Surgical Treatment of Pulmonary Embolism Associated with COVID-19: First-Hand Experience

Abstract

INTRODUCTION: Venous thromboembolic complications occupy one of the central positions in the structure of complications associated with CoronaVirus Disease 2019 (COVID-19). Characterized by high epidemiological threshold values, as well as an atypical clinical picture, they determine the need for new approaches to early diagnosis and active treatment. Surgical treatment of pulmonary embolism in itself is an extremely controversial method of reperfusion of the pulmonary arterial bed. Concerning pulmonary embolism associated with a new coronavirus infection, we did not find a single clinical case reported in the available literature. The article considers a clinical case of surgical treatment of pulmonary embolism against the background COVID-19 infection, demonstrates a comprehensive approach to treatment and describes peculiarities of the clinical picture.

CONCLUSION: Based on the presented case, one should note the importance of the anticoagulant therapy in a group of people with a virus-specific intervention to prevent recurrence of thromboembolic complications. Complex surgical treatment in combination with the proposed methods of anesthesiological support are the methods of choice in a group of people at intermediate-high and high risk of early cardiac death.

Keywords

COVID-19 / pulmonary embolism / coronavirus infection / COVID-associated coagulopathy

References

[1] Claeys MJ, Vandekerckhove Y, Cosyns B, et al. Summary of 2019 ESC Guidelines on chronic coronary syndromes, acute pulmonary embolism, supraventricular tachycardia and dislipidaemias. Acta Cardiol. 2021;76(1):1–8. doi: 10.1080/00015385.2019.1699282

[2] Claeys M.J., Vandekerckhove Y., Cosyns B., et al. Summary of 2019 ESC Guidelines on chronic coronary syndromes, acute pulmonary embolism, supraventricular tachycardia and dislipidaemias // Acta Cardiologica. 2021. Vol. 76, No. 1. P. 1–8. doi: 10.1080/00015385.2019.1699282

[3] Cао X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–70. doi: 10.1038/s41577-020-0308-3

[4] Cао X. COVID-19: immunopathology and its implications for therapy // Nature Reviews. Immunology. 2020. Vol 20, No. 5. P. 269–270. doi: 10.1038/s41577-020-0308-3

[5] Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–99. doi: 10.1111/jth.14817

[6] Tang N., Bai H., Chen X., et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy // Journal of Thrombosis and Haemostasis. 2020. Vol. 18, No. 5. Р. 1094–1099. doi: 10.1111/jth.14817

[7] Llitjos J–F, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743–6. doi: 10.1111/jth.14869

[8] Llitjos J.–F., Leclerc M., Chochois C., et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients // Journal of Thrombosis and Haemostasis. 2020. Vol. 18, No. 7. P. 1743–1746. doi: 10.1111/jth.14869

[9] Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020;75(23):2950–73. doi: 10.1016/j.jacc.2020.04.031

[10] Bikdeli B., Madhavan M.V., Jimenez D., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up // Journal of the American College of Cardiology. 2020. Vol. 75, No. 23. P. 2950–2973. doi: 10.1016/j.jacc.2020.04.031

[11] Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2021;18(6):1421–4. doi: 10.1111/jth.14830

[12] Cui S., Chen S., Li X., et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia // Journal of Thrombosis and Haemostasis. 2021. Vol. 18, No. 6. P. 1421–1424. doi: 10.1111/jth.14830

[13] Dolhnikoff M, Duarte–Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020;18(6):1517–9. doi: 10.1111/JTH.14844

[14] Dolhnikoff M., Duarte–Neto A.N., de Almeida Monteiro R.A., et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 // Journal of Thrombosis and Haemostasis. 2020. Vol. 18, No. 6. P. 1517–1519. doi: 10.1111/JTH.14844

[15] Fogarty H, Townsend L, Cheallaigh CN, et al. COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2021;189(6):1044–9. doi: 10.1111/bjh.16749

[16] Fogarty H., Townsend L., Cheallaigh C.N., et al. COVID-19 coagulopathy in Caucasian patients // British Journal of Haematology. 2021. Vol. 189, No. 6. P. 1044–1049. doi: 10.1111/bjh.16749

[17] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. doi: 10.1016/S0140-6736(20)30251-8

[18] Lu R., Zhao X., Li J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding // Lancet. 2020. Vol. 395, No. 10224. P. 565–574. doi: 10.1016/S0140-6736(20)30251-8

[19] Iba T, Levy J, Levi M, et al. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103–9. doi: 10.1111/jth.14975

[20] Iba T., Levy J.H., Levi M., et al. Coagulopathy in COVID-19 // Journal of Thrombosis and Haemostasis. 2020. Vol. 18, No. 9. P. 2103–2109. doi: 10.1111/jth.14975

[21] Kloka FA, Kruipb MJHA, Van der Meerc NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7. doi: 10.1016/j.thromres.2020.04.013

[22] Kloka F.A., Kruipb M.J.H.A., van der Meerc N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 // Thrombosis Research. 2020. Vol. 191. P. 145–147. doi: 10.1016/j.thromres.2020.04.013

[23] Poissy J, Goutay J, Caplan M, et al. Pulmonary Embolism in COVID19 Patients: Awareness of an Increased Prevalence. Circulation. 2021;142(2):184–6. doi: 10.1161/CIRCULATIONAHA.120.047430

[24] Poissy J., Goutay J., Caplan M., et al. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence // Circulation. 2021. Vol. 142, No. 2. P. 184–186. doi: 10.1161/CIRCULATION AHA.120.047430

[25] Wichmann D, Sperhake J, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020;173(4):268–77. doi: 10.7326/M20-2003

[26] Wichmann D., Sperhake J., Lütgehetmann M., et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study // Annals of Internal Medicine. 2020. Vol. 173, No. 4. P. 268–277. doi: 10.7326/M20-2003

[27] Medvedev AP, Fedorov SA, Trofimov NA, et al. Errors in diagnosis and treatment of pulmonary embolism. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2021;14(1):54 9. (In Russ). doi: 10.17116/kardio20211401154

[28] Медведев А.П., Федоров С.А., Трофимов Н.А., и др. Ошибки диагностики и лечения тромбоэмболии легочной артерии // Кардиология и сердечно-сосудистая хирургия. 2021. Т. 14, № 1. С. 54–59. doi: 10.17116/kardio20211401154

RIGHTS & PERMISSIONS

Fedorov S.A., Zhurko S.A., Pichugin V.V., Chiginev V.A., Maximov A.L., Kulkarni S.V.